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Noroviruses are the most common cause of viral gas-
troenteritis in the United States. To determine the magni-
tude and duration of virus shedding in feces, we evaluated 
persons who had been experimentally infected with Nor-
walk virus. Of 16 persons, clinical gastroenteritis (watery 
diarrhea and/or vomiting) developed in 11; symptomatic 
illness lasted 1–2 days. Virus shedding was ﬁ  rst detected 
by reverse transcription–PCR (RT-PCR) 18 hours after par-
ticipant inoculation and lasted a median of 28 days after 
inoculation (range 13–56 days). The median peak amount 
of virus shedding was 95 × 109 (range 0.5–1,640 ×109) 
genomic copies/g feces as measured by quantitative RT-
PCR. Virus shedding was ﬁ  rst detected by antigen ELISA 
≈33 hours (median 42 hours) after inoculation and lasted 
10 days (median 7 days) after inoculation. Understanding of 
the relevance of prolonged fecal norovirus excretion must 
await the development of sensitive methods to measure vi-
rus infectivity.
N
oroviruses are the most common cause of epidemic 
gastroenteritis in the United States (1). Although in 
vitro replication systems for these viruses have recently 
been described (2,3), human noroviruses cannot readily be 
grown in cell culture, and no small animal model of human 
norovirus infection is available. Much of what is known 
about these viruses has by necessity been learned from ex-
perimental human infection and from observational studies 
of naturally acquired infection. Norwalk virus is the proto-
type strain in the genus Norovirus, and many of the human 
experimental infection studies have used this strain (4–9). 
We describe the duration and magnitude of virus shedding 
in persons infected with Norwalk virus after experimental 
inoculation.
Materials and Methods
Virus Inoculum
Liquid feces from persons who participated in a pre-
vious Norwalk virus challenge study (8) were screened to 
identify samples with high concentrations of Norwalk virus 
RNA (>107 reverse transcription–PCR [RT-PCR] U/mL). 
The participants were recontacted and screened for health 
(results within normal limits for liver function, tubercu-
losis skin test [negative], and chest radiographs; negative 
serologic test results for hepatitis A, B, and C, retroviruses 
[HIV-1, HIV-2, and human T-lymphotropic virus 1 and 2], 
and syphilis [nonreactive rapid plasma regain]). The new 
challenge inoculum (lot 42399) was prepared from liquid 
feces of 1 participant by clariﬁ  cation, centrifugation, and 
serial ﬁ  ltration through ﬁ  lters with progressively smaller 
pore size to a ﬁ  nal 0.45-μm ﬁ  lter size. The inoculum, which 
contained no other enteric viruses or adventitious agents, 
was packaged and stored at –80°C.
Challenge Protocol
Challenge studies were conducted from September 
2004 through October 2006. Healthy adults (18–50 years 
of age) provided informed consent and successfully com-
pleted a test of understanding. In addition, eligible persons 
were secretor positive (because secretor-negative per-
sons are resistant to Norwalk virus infection; 9,10), had 
screening laboratory study results that were within normal 
limits (liver and renal function, blood counts), had nega-
tive serologic results for hepatitis and HIV, had no seri-
ous chronic diseases, had no history of nonbacterial gas-
troenteritis within 3 months of inoculation or of bacterial 
or protozoal enteric infection within 1 month (based on 3 
negative enteric cultures and fecal ova and parasite stud-
ies in the 4-week preinoculation screening period), were 
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not exposed to persons considered to be at risk for more 
severe norovirus infection (e.g., immunocompromised pa-
tients, the elderly, and children), and were not employed 
in jobs identiﬁ  ed as having high risk for transmission to 
other persons (e.g., food service, healthcare, and airline in-
dustries). On the day of inoculation, participants were ad-
mitted to the Baylor College of Medicine General Clinical 
Research Center and orally received different dosages of 
inoculum (10-fold dilutions ranging from 4.8 to 4,800 RT-
PCR units) or placebo in the early evening. Inoculated par-
ticipants remained in the Center for a minimum of 96 hours 
and at discharge had experienced no watery feces or vomit-
ing for at least 18 hours. Participants’ clinical signs and 
symptoms were evaluated every 4 hours while they were 
in the Center, and all fecal samples were collected and re-
frigerated immediately. Within 24 hours of collection, the 
samples were transported to the laboratory for processing 
and stored at –70oC until analyzed. After patient discharge, 
all fecal samples were collected daily for 21 days and then 
weekly for up to 5 additional weeks (for a total observa-
tion time of up to 8 weeks postinoculation). The samples 
were delivered to the laboratory within a day of collection 
and were processed and stored as described above. Partici-
pants were educated about the importance of hand washing 
and hand hygiene at the beginning of the study, and these 
concepts were reinforced at each study visit. The clinical 
protocol was reviewed and approved by the Institutional 
Review Board at Baylor College of Medicine, and an In-
vestigational New Drug application describing the clinical 
protocol and study inoculum was reviewed by the US Food 
and Drug Administration.
Laboratory Studies
Norwalk virus–speciﬁ  c antigen was detected by sand-
wich ELISA, using Norwalk virus–speciﬁ  c antiserum, as 
previously described (8), and Norwalk virus–speciﬁ  c an-
tibody was detected by ELISA, using Norwalk virus–like 
particles as antigen, as previously described (8). Norwalk 
virus RNA was detected in fecal specimens by using either 
an immunomagnetic capture (IMC) RT-PCR assay (11) or 
quantitated by real-time RT-PCR (qRT-PCR) with RNA 
transcripts as a standard (2). The primers used for the IMC 
RT-PCR assay were the antisense Norwalk virus p35 (5′-
CTT GTT GGT TTG AGG CCA TAT-3′) and the sense 
Norwalk virus p36 (5′-ATA AAA GTT GGC ATG AAC 
A-3′); probe was a 5′ digoxigenin-labeled Norwalk virus 
p69 (5′-GGC CTG CCA TCT GGA TTG CC-3′). For the 
qRT-PCR assay, a 10% fecal sample was diluted 1,000-
fold and heated to 95oC for 5 min (12); 20 μL of heated 
sample was analyzed in duplicate wells. The primers for 
the qRT-PCR assay were the antisense Norwalk virus p165 
(5′-CAT AAT CAC CTA CAT CCA TCT CAG ATG-3′, 
which is complementary to Norwalk virus nt 4689–4715) 
and the sense primer Norwalk virus p166 (5′-CGG CCT 
CAC CAG AAT TGG-3′, which is complementary to Nor-
walk virus nt 4641–4658); the probe was Norwalk virus 
p167 (5′-FAM/CGA GGT TGT GGC CCA AGA TTT 
GCT AG/TAMRA-3′, which is complementary to nt 4660–
4685). For determination of a virus titer, both wells had 
to show ampliﬁ  cation. The limits of detection for the IMC 
RT-PCR and qRT-PCR assays were ≈15 × 103 and ≈40 × 
106 copies/g feces, respectively.
Deﬁ  nitions
Infection was deﬁ  ned as seroresponse (4-fold rise in 
titer from preinoculation baseline to 30-day serum sample, 
as measured by ELISA) or fecal virus excretion as detected 
by RT-PCR or presence of antigen. Viral gastroenteritis 
was deﬁ  ned as illness with moderate diarrhea (alone) for 
any continuous 24-hour period (moderate diarrhea is >200 
g of watery feces that immediately take the shape of the 
collection container) or 1 vomiting episode plus 1 of the 
following: abdominal cramps or pain, nausea, bloating, 
loose feces (if not fulﬁ  lling the deﬁ  nition of diarrhea), fever 
(oral temperature >37.6°C), myalgia, or headache.
Results
A total of 16 persons inoculated with Norwalk virus 
met the criteria for having Norwalk virus infection. Of 
these, 11 (69%) met the predeﬁ  ned deﬁ  nition for viral 
gastroenteritis. The 5 who did not meet this predeﬁ  ned 
deﬁ  nition had >3 symptoms that did not include vomit-
ing or >200 g of watery diarrhea. All 11 participants with 
viral gastroenteritis had abdominal cramps, nausea, and 
vomiting; 5 of these participants also had >200 g of wa-
tery diarrhea, and 1 had <200 g of watery feces. Other 
signs and symptoms in the 11 participants were malaise 
(n = 9), anorexia (n = 8), headache (n = 7), myalgia (n = 
4), temperature >37.6oC (n = 4), and chills (n = 3). The 5 
participants who did not fulﬁ  ll the criteria for gastroen-
teritis had nausea (n = 5), anorexia (n = 5), malaise (n = 
4), abdominal cramps (n = 3), myalgia (n = 3), headache 
(n = 3), temperature >37.6oC (n = 2), chills (n = 2), and 
watery diarrhea <200 g (n = 2). Although the number of 
infected participants in each dosage group was relatively 
small, no differences in signs and symptoms based on 
inoculum dosage were apparent. The median duration of 
signs and symptoms was 23 (range 10–61) hours and was 
similar for both groups of participants.
All infected participants shed virus as measured by 
RT-PCR and had a >4-fold rise in serum antibody level, 
and all but 2 also shed virus as measured by antigen ELISA 
(Table). Virus shedding as measured by IMC RT-PCR was 
ﬁ  rst detected a median of 36 hours (range 18–110 hours) 
after inoculation and lasted a median of 28 days after in-
oculation (range 13–56 days). Norwalk virus was detected 
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in fecal samples of 7 participants 3–14 hours before onset 
of any clinical signs or symptoms. Presymptomatic shed-
ding was more common in persons who did not meet the 
deﬁ  nition of clinical gastroenteritis than in those who did 
(4/5 vs. 3/11, respectively, p = 0.11, 2-tailed Fisher exact 
test). Virus shedding as measured by antigen ELISA was 
ﬁ  rst detected ≈33 hours (median 42 hours) after inocula-
tion and was last detected 10 days (median 7 days) after 
inoculation. Median values of the onset and resolution of 
virus shedding, as measured by IMC RT-PCR or antigen 
ELISA, were similar for the participants who had clinical 
gastroenteritis compared with those of persons who did not 
meet the deﬁ  nition of gastroenteritis (Table).
Norwalk virus concentration in feces, as measured by 
qRT-PCR, peaked a median of 4 days after inoculation; 
the time of peak shedding was similar for participants who 
did and did not meet the deﬁ  nition of viral gastroenteritis 
(Table). The highest fecal concentrations of virus were de-
tected in 11 (69%) participants after their clinical signs had 
resolved. The median peak amount of virus shedding was 
95 × 109 (range 0.5–1,640 × 109) genomic copies/g feces, 
and 5 participants shed >100 × 106 copies/g until at least 
day 14 (Figure 1). Persons who met the clinical deﬁ  nition 
of gastroenteritis had a higher median peak of virus shed-
ding than those who did not have gastroenteritis (250 × 109 
vs. 12 × 109 genomic copies/g feces, p = 0.08, Wilcoxon 
rank sum), and the average total number of viral genomic 
copies measured in the feces over the ﬁ  rst 2 weeks after 
inoculation also was higher in the clinical gastroenteritis 
group (1013.3 vs. 1012.4, p = 0.056, Student t test). The vi-
rus concentrations in feces collected later after inoculation 
were low (range 225,000–40 × 106 genomic copies/g). Cor-
relation between virus titer in feces and optical density re-
sults obtained in the antigen ELISA was strong (r = 0.823, 
Pearson correlation, p<0.001; Figure 2).
Discussion
Noroviruses are estimated to cause 23 million cases 
of gastroenteritis in the United States each year and to be 
the most common cause of foodborne gastroenteritis (13). 
Relatively few data describe the quantity and duration of 
fecal norovirus shedding as determined by modern assays. 
In a human experimental Norwalk virus infection model, 
we found that Norwalk virus could be detected in fecal 
samples for a median of 4 weeks and for up to 8 weeks 
after virus inoculation and that peak virus titers were most 
commonly found in fecal samples collected after resolu-
tion of symptoms. The peak virus titers (median 95 × 109 
copies/g feces) were higher than would be expected from 
electron microscopic studies (5,14). These observations 
help explain the epidemiologic observations of norovirus 
outbreaks linked to food handlers who had recovered from 
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 10, October 2008  1555 
Table. Fecal virus shedding among 16 participants inoculated with Norwalk virus* 
Participant
no.
Estimated Norwalk 
virus inoculum dose 
(RT-PCR units) 
First–last study days† 
postinoculation when 
symptoms present 
First–last study 
days IMC  
RT-PCR positive 
Day peak virus 
titer (character 
of feces) 
Peak qRT-
PCR virus 
titer (log10/g) 
First–last study days 
postinoculation when 
antigen positive 
Met clinical definition of gastroenteritis 
  Had diarrhea and vomiting 
  706  4,800 2 2–28‡ 2  (liquid)  11.1 2–9
  707  4,800 2–4 1–30‡ 2  (liquid)  9.5 4–8
  710  4,800 1–2 2–30‡ 5  (solid)  10.9 2–7
  722  48 2 2–48 4  (solid)  11.7 2–8
  724  4.8 2–3 2–56 3  (solid)  11.4 2–6
  Had vomiting only 
  701  4,800 1–2 1–29‡ 4  (solid)  10.8 3–10
  720§  48 2 2–56 4  (solid)  11.5 2–9
  721  48 1–3 2–21 4  (solid)  11.7 2–10
  723  48 2 1–50 4  (solid)  12.2 2–6
  731  4.8 2–3 5–10 5  (solid)  10.0 None
  732  4.8 2–3 2–15 3  (solid)  11.9 2–6
 Median  – 2 2–30‡ 4  (solid)  11.4 2–8
Did not meet clinical definition of gastroenteritis 
703 4,800 2–3 1–32‡ 2 (solid) 10.7 2–9
 704  4,800 2–3 4–21‡ 5  (solid)  9.2 5–7
 715§  48 2–3 1–28 3  (solid)  11.7 2–5
 716§  48 2–3 1–20 4  (unformed)  10.1 3–7
 717  48 3 4–13 4  (solid)  9.3 None
 Median  – 2–3 1–21‡ 4  (solid)  10.1 2–7
*RT–PCR, reverse transcription–PCR; IMC, immunomagnetic capture; qRT-PCR, quantitative PCR. 
†Study days are reported as calendar days; study day 1 began |5–6 h postinoculation. 
‡Fecal samples only collected for 30 d postinoculation. 
§Watery feces with mass <200 g. RESEARCH
symptomatic infection (15) and in persons who had no gas-
troenteritis (16).
Only a few studies have used quantitative RT-PCRs to 
examine fecal viral load, and these studies have been pri-
marily of GII norovirus strains. Chan et al. (17) described 
patients who shed >1011 norovirus copies/g feces, whereas 
the peak fecal virus titer observed by Ozawa et al. (18) in 
symptomatic and asymptomatic food handlers was ≈10-fold 
lower. Each of these studies was of persons with naturally 
acquired norovirus infection. However, the median peak vi-
ral load observed in our study (1011) was much higher than 
the 107–108 median viral loads reported in the prior studies 
(17,18). Lee et al. (19) noted higher viral loads in patients 
who had more prolonged symptoms (>4 days) associated 
with infection caused by GII.4 norovirus. Amar et al. (20) 
also reported viral loads to be higher in persons who had 
symptomatic gastroenteritis than in those who had been 
asymptomatic for at least 3 weeks. Our ﬁ  ndings suggest 
that clinical gastroenteritis was associated with higher peak 
virus shedding and higher total virus shedding during the 
ﬁ  rst 2 weeks after inoculation. Although we did not see an 
association of peak virus titer with symptom duration, the 
median duration of symptoms averaged only ≈1 day in our 
study. Potential reasons for the different results observed 
in other studies include the manner in which samples were 
collected (single samples vs. serial collection), the real-
time assays used (generic assays designed to be broadly 
reactive vs. assay designed speciﬁ  cally for Norwalk virus 
detection), virulence of the infecting strains, differences in 
the populations studied (e.g., age, immune status), and the 
small number of infected persons who did not have clinical 
gastroenteritis in our study.
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Figure 1. Shedding of Norwalk virus in feces. The quantity of viral RNA measured by quantitative reverse transcription–PCR (qRT-PCR; 
black line) and of virus antigen measured by ELISA (optical density; blue line) is shown for 2 participants: no. 703, who did not have clinical 
gastroenteritis (panel A), and no. 721, who had clinical gastroenteritis (panel B). Vertical lines represent the period of clinical symptoms; N, 
nausea; V, vomiting. Panels C, D, and E show the virus titers as measured by qRT-PCR in fecal samples collected from participants who 
had no clinical gastroenteritis, had gastroenteritis with vomiting only, and had gastroenteritis with vomiting and diarrhea, respectively.
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Figure 2. Correlation of viral RNA titer with antigen ELISA (optical 
density [OD]). Titers of viral RNA are correlated with the OD 
measured by antigen ELISA for the 148 fecal samples with positive 
quantitative reverse transcription–PCR (qRT-PCR) results (r2 = 
0.823, Spearman correlation, p<0.001).Norwalk Virus Shedding after Experimental Infection
The development of more sensitive methods to detect 
noroviruses has been associated with a corresponding in-
crease in the duration of recognized virus shedding (1,8). 
For example, Rockx et al. (21) found norovirus in fecal 
samples for >3 weeks in ≈25% of infected persons, and 
Murata et al. (22) found norovirus in fecal samples for up 
to 6 weeks in infected infants. In contrast, at least half of 
the participants in our study still had Norwalk virus in fe-
cal samples after 4 weeks and 2 had virus still present at 8 
weeks; we cannot exclude the possibility that these 2 per-
sons shed for a longer period. Determination of whether the 
virus is still infectious must await the development of more 
sensitive and reproducible methods for norovirus cultiva-
tion than are currently available (23). 
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